1. In Vivo
  2. >>Archive

Inflection Point For Regen Med Lauded At London ARM Meeting

 
• By Ashley Yeo

Insights from the Alliance for Regenerative Medicine's fifth annual EU Advanced Therapies Investor Day, held in London in November 2017.

The fifth annual European investor meeting of the Alliance for Regenerative Medicine (ARM) – the fourth to be held in London – reported on 934 clinical trials ongoing worldwide (industry- and investigator-led trials), of which 79 are in Phase III, and 548 in Phase II. Eleven regen med products have gained regulatory approval.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Archive

More from In Vivo

Podcast: Ochre Bio’s Approach To Precision Medicine In Liver Treatment

 
• By David Wild

Ochre Bio co-founder and CSO Quin Wills spoke with In Vivo about the UK-based company's novel approach to finding RNA therapies for chronic liver disease.

Richard DiMarchi On The GLP-1 Revolution: An Overnight Success After 40 Years

 
• By Andrew Warmington

As GLP-1 agonists surge to blockbuster status transforming diabetes and obesity treatment, Richard DiMarchi, the pioneering scientist behind their development, recounts the inside story of the drug class in a fireside chat.

Rising Leaders 2025: João Ribas On Building At The Intersection Of Science And Business

 
• By Jo Shorthouse

João Ribas combines scientific expertise with venture capital at Novo Holdings, applying his dual background to develop biotech investments that connect academic research with commercial opportunity.